- June 2016
Key advances in clinical trials.
- May 2016
Mark Lemmon on the underlying biochemistry of cancer.
- April 2016
Roger Stupp on using alternating electric fields as treatment.
- March 2016
Charlotte Vrinten on public perception of deaths from cancer.
- February 2016
Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
- December 2015/January 2016
Nazneen Rahman on germline genetic screening in ovarian cancer.
- November 2015
Caroline Robert on new developments in immunotherapy.
- October 2015
Milena Sant on the latest results from the EUROCARE study.
- September 2015
The science behind the IARC code that could reduce cancer in Europe.
- July/August 2015
Thomas Helleday on an exciting new class of drug, MTH1 inhibitors.
- June 2015
Lesley Seymour and Jan Bogaerts on the future of RECIST.
- May 2015
Paul Workman on strategies for overcoming resistance to new drugs.
- April 2015
Highlights from the TAT Congress in Paris.
- March 2015
Christopher Wild on the exposome, a measure of environmental exposure.
EJC News Focus – May 2013
Highlights of 2nd ESTRO Forum
By the year 2020, it is estimated that for every tumour, data will be available on 10,000 markers related to survival. How are clinicians to make sense – and practical use – of it all?
According to ESTRO President, Vincenzo Valentini, a good way to start might be to involve radiation oncologists who already have expertise in complex imaging and dose-planning models. The decision models of the future will become even more sophisticated, he says, able to codify quality of life so that the needs of individual patients can be met.
This was just one of the themes of the 2nd ESTRO Forum (Geneva; 19-23 April 2013). Others included the combination of radiation therapy and drugs; and the use of a single shot of radiotherapy to control pain. Here Vincenzo Valentini discusses the highlights of the forum with Helen Saul.